Cardio Diagnostics Holdings Inc. CDIO Archives

MondayMay 18, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is Focused on Vision for Personalized Heart Care

CDIO’s vision reflects a broader shift taking place across the healthcare industry toward predictive and Precision Medicine. Achieving that goal requires a combination of scientific expertise, advanced technology, scalable testing and improved accessibility. Cardio Diagnostics’ focus on innovation is particularly relevant in cardiovascular disease, where earlier identification of risk factors can significantly influence outcomes. Heart disease remains the leading cause of death worldwide, yet much of modern healthcare still focuses on reacting to cardiovascular events after they occur rather than identifying risk earlier and preventing disease progression. Cardio Diagnostics Holdings (NASDAQ: CDIO) is working to help reshape that paradigm through a vision…

FridayMay 15, 2026 11:55 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood sample, positioning itself at the intersection of precision medicine and preventive care,” reads a recent article. “Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. The…

FridayMay 15, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies. Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care. This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes. Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights…

WednesdayMay 06, 2026 1:16 pm

QualityStocksNewsBreaks – AI Meets Multi-Omics: Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Earlier, More Precise Cardiac Insights

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. “Cardio Diagnostics Holdings is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (‘AI’) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions,” the publication reads. “Despite advances in medicine, a key challenge in managing cardiovascular disease is that it often develops silently over…

FridayMay 01, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential. The prevalence of cardiovascular risk factors illustrates the scale of the issue. Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands. Cardio Diagnostics Holdings (NASDAQ: CDIO) is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized…

ThursdayApr 30, 2026 1:54 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample,” reads a recent article. “At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional…

MondayApr 27, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and…

FridayApr 24, 2026 11:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health. The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. CDIO’s focus on accessibility and scalability is also notable. Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a…

FridayApr 17, 2026 12:37 pm

QualityStocksNewsBreaks – Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”…

WednesdayApr 08, 2026 10:20 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Engages IBN to Support Corporate Communications Strategy

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights, including Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence and CardioInnovate360(TM) to support cardiovascular therapy development. To view the full press release, visit https://ibn.fm/hFqWS About Cardio Diagnostics Cardio Diagnostics is…

Site Search

Company Search

Tag: Cardio Diagnostics Holdings Inc. CDIO